Reproductive Health Science (ASX:RHS) has launched its lead product, EmbryoCellect at an international forum for reproductive medicine and embryology in Munich, Germany.
RHS is one of 134 exhibitors at the 2014 European Society of Human Reproduction and Embryology Conference which is a key forum for the IVF community attended by more than 8,500 international delegates.
There has been significant interest in the EmbryoCellect product driven by the increasing awareness and use of Pre-Implantation Genetic Screen during the IVF process and the clinical data demonstrating its positive effects on success rates.
The positive response EmbryoCellect is receiving is coming from both IVF clinics and distributors.
EmbryoCellect is a kit that has an immediate application to improve the success rate of In-Vitro Fertilisation. RHS has developed this test specifically to assess embryos for chromosomal number prior to implantation as part of an IVF cycle.
Capitalised at $10 million and with a global application RHS may be in the early stages of something bigger.
